Cardiotoxicity, hERG channel blockage
Test concentrations: 16
Time points: 2 - 24 h
Replicates: 1
Positive control
Fluorescence analysis
Background
Cardiotoxicity is one of the main reasons for safety-related compound attrition and drug withdrawals, and therefore should be screened in the early stages of drug discovery. We offer a cost-efficient and rapid screening tool for evaluating cardiotoxicity as a part of our toxicity screening portfolio. Full electrophysiological cardiac safety panel is available via a partner.
